APOE and neurodegenerative disease: Structural alterations in ApoE’s receptor-binding domain, such as those resulting from the L122P or L107P variants, may disrupt its interaction network, potentially impairing Aβ homeostasis and diminishing neuroprotective capacity, thereby contributing to neurodegenerative disease mechanisms.